although
vaccin
effect
way
prevent
infect
ever
sinc
eighteenth
centuri
gener
therapeut
vaccin
immunotherapi
still
work
progress
number
challeng
imped
develop
therapeut
approach
safeti
issu
relat
administr
whole
pathogen
whether
attenu
inactiv
one
safe
altern
classic
vaccin
method
gain
recognit
use
nanoparticl
whether
synthet
natur
deriv
recent
demonstr
papaya
mosaic
viru
papmv
like
nanoparticl
use
prophylact
vaccin
variou
viral
bacteri
infect
induct
protect
humor
cellular
immun
respons
moreov
papmv
also
effici
use
immun
adjuv
immunotherapeut
set
slow
growth
aggress
mous
melanoma
tumor
type
interferon
ifni
depend
manner
present
studi
interest
exploit
capac
papmv
induc
robust
ifni
product
treatment
chronic
viral
infect
model
lymphocyt
choriomening
viru
lcmv
clone
treatment
lcmv
mice
two
system
administr
papmv
ineffect
shown
lack
chang
viral
titer
immun
respons
lcmv
follow
treatment
moreov
product
follow
papmv
administr
almost
complet
abolish
lcmvinfect
mice
better
isol
mechan
play
determin
influenc
pretreat
papmv
secondari
papmv
administr
therefor
elimin
potenti
variabl
eman
infect
pretreat
papmv
led
outcom
lcmv
infect
product
follow
secondari
papmv
immun
abrog
day
immun
activ
also
dramat
impair
show
two
distinct
overlap
mechan
respons
outcom
shortterm
inhibit
partial
result
receptorassoci
kinas
degrad
crucial
compon
tolllik
receptor
signal
pathway
longterm
inhibit
mainli
due
interfer
papmvspecif
antibodi
thu
identifi
possibl
pitfal
use
viruslik
particl
system
treatment
chronic
viral
infect
discuss
mitig
altern
circumv
potenti
problem
keyword
plasmacytoid
dendrit
cell
papmv
antibodi
lymphocyt
choriomening
viru
clone
immun
toler
induc
viral
nanoparticl
frontier
immunolog
wwwfrontiersinorg
januari
volum
articl
introduct
type
interferon
ifni
mainli
famili
cytokin
potent
antivir
immunomodulatori
properti
effect
cytokin
milieu
complex
affect
multipl
cell
immun
system
induc
activ
dendrit
cell
dc
ii
sustain
activ
cell
iii
induc
differenti
b
cell
antibodi
secret
cell
thu
earli
ifni
product
essenti
control
viral
infect
mous
hepat
viru
mhv
lymphocyt
choriomening
viru
lcmv
simian
immunodefici
viru
siv
howev
wherea
earli
transient
express
ifni
control
infect
prolong
exposur
bear
detriment
effect
host
immun
respons
balanc
act
posit
neg
effect
ifni
respons
observ
clinic
set
display
welldocu
advers
effect
ifn
therapi
thu
despit
standardofcar
variou
diseas
emerg
therapi
focu
ifnfre
altern
upon
viral
infect
plasmacytoid
dc
pdc
character
main
produc
ifni
review
ref
major
characterist
mainli
due
tolllik
receptor
tlr
express
profil
innat
immun
cell
express
wide
array
tlr
pdc
mainli
express
endosom
bind
genet
materi
typic
associ
viral
pathogen
ssrna
unmethyl
dna
respect
receptor
also
capabl
recogn
analog
natur
ligand
imidazoquinolin
cpg
respect
product
ifni
pdc
also
serv
bridg
innat
adapt
immun
respons
illustr
abil
activ
natur
killer
cell
dc
well
cell
consequ
upon
pdc
deplet
mice
becom
highli
suscept
viral
infect
mhv
herp
simplex
viru
lcmv
vesicular
stomat
viru
murin
cytomegaloviru
among
other
har
central
role
pdc
demonstr
potenti
use
plant
viruslik
nanoparticl
vaccin
candid
well
adjuv
variou
infecti
model
platform
base
papaya
mosaic
viru
papmv
nanoparticl
contain
nonrepl
synthet
ssrna
render
safe
futur
human
use
synthet
ssrna
found
insid
capsid
recogn
pdc
lead
product
along
cytokin
chemokin
papmv
resultantli
activ
dc
macrophag
cell
well
b
cell
make
platform
versatil
activ
immun
system
furthermor
shown
papmv
induc
protect
immun
respons
pathogen
use
vaccin
platform
adjuv
slow
melanoma
develop
use
immunotherapeut
set
consid
papmv
induc
strong
ifni
respons
sought
evalu
potenti
immun
adjuv
treatment
chronic
viral
infect
object
replac
exogen
administr
endogen
secret
follow
system
papmv
deliveri
approach
would
provid
univers
applic
immun
stimulatori
molecul
could
use
viral
infect
without
requir
express
defin
viral
antigen
observ
treatment
mice
chronic
infect
persist
strain
lcmv
papmv
unabl
clear
infect
moreov
multipl
administr
papmv
induc
immun
toler
shown
almost
complet
abrog
product
follow
secondari
papmv
administr
show
toler
result
combin
factor
includ
receptorassoci
kinas
iraki
degrad
interfer
papmvspecif
antibodi
inform
crucial
clinic
develop
papmv
platform
studi
perform
accord
canadian
council
anim
care
guidelin
vivo
experi
review
approv
institut
nation
de
la
recherch
scientifiqu
anim
care
committe
femal
mice
purchas
charl
river
laboratori
jht
mice
kindli
provid
dr
rolf
zinkernagel
zurich
univers
switzerland
lymphocyt
choriomening
viru
kindli
provid
dr
rolf
zinkernagel
zurich
univers
switzerland
fibroblast
cultur
minim
essenti
medium
earl
salt
wisent
stbruno
qc
canada
contain
heat
inactiv
fetal
bovin
serum
fb
paa
laboratori
mississauga
canada
papmv
nanoparticl
provid
folia
biotech
quebec
qc
canada
produc
describ
briefli
coat
protein
self
assembl
vitro
around
noncod
ssrna
lipopolysaccharid
lp
contamin
alway
endotoxin
unitsmg
protein
consid
neglig
mice
infect
pfu
lcmv
iv
treat
papmv
iv
day
serum
collect
h
follow
treatment
assess
product
blood
immun
toler
induc
viral
nanoparticl
frontier
immunolog
wwwfrontiersinorg
januari
volum
articl
collect
day
postinfect
dpi
mononuclear
cell
isol
densiti
gradient
ficollpaqu
ge
healthcar
life
scienc
mississauga
canada
centrifug
rpm
min
room
temperatur
cell
collect
wash
pb
stain
min
pe
tetram
synthes
previous
describ
label
cell
specif
mhci
epitop
lcmv
extracellular
stain
perform
unwash
cell
min
follow
wash
cell
fix
fixat
buffer
biolegend
san
diego
ca
usa
min
room
temperatur
analyz
flow
cytometri
bdlsr
fortessa
bd
bioscienc
mississauga
canada
spleen
collect
dpi
disrupt
frost
microscop
slide
cell
stain
assess
cell
cell
describ
cell
also
incub
brefeldin
bfa
sigma
oakvil
canada
h
inhibit
vesicular
transport
spleen
cell
stain
intracellular
cytokin
product
see
blood
spleen
kidney
liver
brain
also
collect
dpi
assess
viral
burden
organ
mechan
disrupt
supernat
titter
cell
focu
form
assay
assess
viral
burden
previous
describ
spleen
bone
hind
leg
collect
variou
time
point
follow
immun
spleen
subject
digest
mgml
collagenas
roch
mississauga
canada
min
femur
tibia
iliac
crest
flush
singl
cell
suspens
spleen
bone
marrow
subject
red
blood
cell
lysi
follow
flow
cytometri
stain
bone
marrowderiv
pdc
prepar
flush
bone
marrow
femur
tibia
iliac
crest
subject
red
blood
cell
lysi
cell
seed
cellsml
rpmi
wisent
contain
fb
iu
penicillin
ml
streptomycin
wisent
mm
sodium
pyruv
mem
nonessenti
amino
acid
mm
hepe
gibco
supplement
ngml
bioxcel
lebanon
pa
usa
day
cell
stimul
papmv
imiquimod
invivogen
polyinosin
polycyticyl
acid
poli
c
invivogen
control
day
supernat
frozen
detect
cell
stain
flow
cytometri
analysi
cell
sort
mice
immun
papmv
iv
day
day
mice
euthan
blood
collect
cardiac
punctur
blood
allow
clot
min
room
temperatur
tube
centrifug
g
min
room
temperatur
sera
pool
inject
ip
mice
wherebi
serum
two
mice
use
inject
one
mous
h
mice
immun
papmv
control
iv
serum
collect
h
later
quantifi
papmvspecif
antibodi
activ
pdc
assess
spleen
h
postimmun
analysi
surfac
antigen
perform
follow
antibodi
marker
mice
immun
papmv
iv
describ
spleen
bone
marrow
collect
h
postimmun
process
describ
cell
incub
bfa
h
follow
intracellular
stain
describ
bone
marrowderiv
pdc
stimul
h
stain
sort
fc
receptor
block
previous
describ
pdc
identifi
cell
collect
fb
wash
twice
cold
pb
follow
protein
extract
see
sort
perform
use
bd
facsjazz
bd
bioscienc
immunoblot
immunoblot
cell
harvest
lyse
triton
lysi
buffer
mm
trishcl
ph
triton
glycerol
mm
nacl
proteas
inhibitor
cocktail
roch
lysat
load
sdspage
follow
transfer
polyvinyliden
difluorid
membran
biorad
mississauga
canada
membran
block
dri
milk
tbst
tb
h
room
temperatur
primari
antibodi
mous
cell
signal
technolog
dilut
tbst
incub
membran
antirabbit
igg
hrp
jackson
immunoresearch
west
grove
pa
usa
use
secondari
antibodi
wherebi
dilut
tbst
incub
membran
h
room
temperatur
detect
perform
ecl
chemiluminesc
kit
biorad
level
mice
serum
cell
cultur
supernat
quantifi
elisa
accord
manufactur
direct
affymetrix
ebiosci
kc
gcsf
mcsf
rant
level
mice
serum
quantifi
use
milliplex
map
mous
cytokinechemokin
premix
plex
millipor
etobicok
canada
accord
manufactur
direct
measur
median
fluoresc
intens
mfi
perform
use
bioplex
biorad
papmvspecif
antibodi
titer
determin
describ
previous
detect
papmvspecif
igm
perform
peroxidaseconjug
goat
antimous
igm
jackson
immunoresearch
laboratori
statist
analysi
perform
graphpad
prism
softwar
graphpad
softwar
error
bar
repres
sem
twotail
student
ttest
use
welch
correct
appli
need
impact
viral
infect
mice
shown
vari
accord
kinet
strength
product
ongo
infect
earli
shown
essenti
control
infect
longterm
detriment
host
favor
viral
persist
one
studi
treatment
lcmv
mice
exogen
day
postinfect
result
increas
cell
well
decreas
viral
load
dpi
led
us
hypothes
treatment
chronic
infect
lcmv
papmv
could
result
similar
clearanc
viru
given
capac
papmv
induc
potent
product
follow
immun
therefor
infect
mice
lcmv
treat
dpi
papmv
iv
blood
collect
variou
time
point
assess
viral
load
affect
treatment
papmv
figur
assess
effici
papmv
treatment
serum
collect
h
follow
treatment
day
quantifi
elisa
although
administr
papmv
induc
strong
product
naiv
mice
lcmv
mice
bare
produc
figur
whether
assess
first
treatment
day
second
treatment
day
result
indic
infect
lcmv
hinder
product
follow
papmv
administr
note
papmv
induc
immun
mice
also
cytokin
chemokin
reli
differ
set
signal
pathway
product
therefor
possibl
immun
cell
activ
auxiliari
cytokin
follow
treatment
papmv
despit
absenc
detect
serum
test
assess
activ
cell
well
proport
cell
proport
cell
blood
day
postinfect
similar
group
treat
control
papmv
figur
similar
trend
notic
express
cell
figur
also
assess
exhaust
cell
mean
express
increas
mice
treat
papmv
compar
mice
treat
control
figur
express
cell
reduc
papmv
compar
mice
treat
control
figur
togeth
data
indic
treatment
lcmv
mice
papmv
day
increas
activ
cell
howev
treatment
seem
increas
exhaust
cell
indic
increas
express
inhibitori
receptor
papmv
treatment
lead
home
cell
lymphoid
organ
shown
decreas
express
adhes
molecul
involv
home
lymphocyt
secondari
lymphoid
organ
percentag
cell
differ
day
postinfect
control
papmvtreat
group
figur
well
express
significantli
differ
two
group
figur
furthermor
result
reveal
function
cell
affect
treatment
lcmv
infect
papmv
shown
similar
percentag
posit
cell
spleen
figur
control
papmvtreat
group
confirm
papmv
treatment
effect
clearanc
lcmv
collect
lymphoid
nonlymphoid
organ
dpi
assess
viral
load
lcmv
spleen
kidney
liver
brain
group
display
similarli
elev
lcmv
titer
figur
along
previou
data
indic
treatment
papmv
ineffect
clear
lcmv
infect
notabl
shown
cell
previous
infect
chronic
virus
hepat
b
viru
hbv
hepat
c
viru
hcv
unrespons
tlr
ligand
stimul
base
find
surmis
possibl
tlr
toler
mechan
might
play
lcmv
infect
therefor
hinder
activ
immun
cell
subsequ
tlr
ligand
stimul
papmv
lymphocyt
choriomening
viru
clone
activ
immun
cell
endosom
pathway
well
cytosol
pathway
order
exclud
activ
cytokin
product
caus
engag
pathway
decid
move
papmvonli
base
model
stimul
therefor
pretreat
mice
papmv
differ
time
interv
rang
day
prior
second
immun
papmv
sera
collect
h
follow
second
immun
assess
product
elisa
singl
administr
papmv
induc
strong
product
detect
serum
h
postimmun
figur
mice
pretreat
papmv
product
abolish
follow
secondari
immun
day
follow
pretreat
figur
similar
hindranc
observ
product
wherea
product
enhanc
unaffect
respect
figur
supplementari
materi
similarli
product
variou
chemokin
growth
factor
also
suppress
follow
second
immun
observ
product
mcsf
rant
wherea
product
kc
gcsf
enhanc
unaffect
figur
supplementari
materi
cytokin
chemokin
differenti
regul
upon
papmv
administr
focus
product
base
widerang
use
therapeut
set
sinc
pdc
major
produc
upon
stimul
ligand
sought
determin
whether
absenc
due
lack
activ
pdc
spleen
mice
pretreat
papmv
collect
h
follow
second
immun
activ
pdc
assess
flow
cytometri
seen
product
singl
immun
papmv
induc
upregul
figur
pdc
convers
mice
pretreat
papmv
day
prior
second
immun
pdc
unabl
respond
second
immun
observ
absenc
upregul
figur
found
express
activ
marker
pdc
day
pretreat
due
remnant
initi
immun
rather
activ
pdc
follow
second
immun
figur
supplementari
materi
lag
pretreat
second
immun
pdc
activ
second
immun
although
lesser
intens
mice
treat
papmv
figur
altogeth
result
demonstr
administr
papmv
induc
refractori
state
pdc
render
unabl
respond
papmv
immun
short
interv
effect
complet
inhibitori
longer
interv
inhibit
partial
indic
distinct
mechan
possibl
concomitantli
interf
respons
refractori
state
induc
papmv
pretreat
affect
respons
ligand
assess
whether
refractori
state
induc
pretreat
papmv
affect
administr
papmv
pretreat
mice
papmv
challeng
day
later
lp
poli
c
ligand
respect
assess
express
pdc
figur
expect
mice
treat
lp
poli
c
alon
show
upregul
pdc
indic
activ
mice
pretreat
papmv
subsequ
immun
lp
effici
induc
activ
pdc
immun
naiv
anim
still
show
degre
upregul
result
indic
inhibit
induc
pretreat
papmv
impact
subsequ
immun
papmv
also
ligand
well
tlr
pathway
although
inhibit
less
pronounc
strikingli
unlik
inhibit
observ
lp
administr
papmv
prior
poli
c
result
express
indic
pdc
activ
similar
control
treat
group
figur
altogeth
result
point
toward
inhibitori
mechan
induc
papmv
pretreat
affect
pathway
pathway
remain
unaffect
tolllik
receptor
pathway
specif
receptor
inde
complex
implic
signal
cascad
share
across
pathway
review
ref
papmv
affect
signal
pathway
tlr
signal
pathway
would
also
affect
result
crossinhibit
observ
cell
pretreat
papmv
inde
crossinhibit
observ
respons
stimul
variou
tlr
ligand
ligand
ligand
ligand
establish
presenc
homo
hetero
toler
tlr
signal
pathway
studi
one
common
mechan
report
involv
observ
cross
toler
degrad
kinas
implic
tlr
signal
pathway
therefor
exclud
signal
pathway
therefor
assess
express
pdc
flow
cytometri
immunoblot
analyz
regul
follow
papmv
stimul
given
pdc
account
splenocyt
evalu
respons
pdc
papmv
vitro
use
bmpdc
differenti
bone
marrow
cell
day
cell
stimul
papmv
similar
observ
vivo
splenic
pdc
bmpdc
readili
activ
variou
tlr
ligand
includ
papmv
shown
upregul
figur
accumul
cultur
supernat
follow
stimul
figur
sinc
papmv
activ
bmpdc
investig
regul
follow
stimul
variou
tlr
ligand
first
assess
express
flow
cytometri
follow
variou
incub
period
bmpdc
ligand
papmv
ligand
poli
c
expect
induc
strong
downregul
h
bmpdc
vitro
figur
e
surprisingli
stimul
bmpdc
poli
c
induc
small
downregul
start
h
poststimul
stimul
bmpdc
papmv
induc
degrad
albeit
lesser
extent
slower
kinet
figur
e
confirm
modul
express
sort
pdc
h
poststimul
papmv
poli
c
extract
total
cellular
protein
evalu
express
immunoblot
found
h
express
undetect
figur
stimul
poli
c
induc
degrad
figur
also
degrad
follow
stimul
bmpdc
papmv
although
extent
degrad
lower
comparison
observ
figur
compar
express
ratio
obtain
western
blot
flow
cytometri
tabl
figur
f
notic
similar
ratio
two
assay
papmv
stimul
bmpdc
ratio
vari
poli
c
stimul
bmpdc
taken
togeth
result
indic
papmv
induc
degrad
pdc
could
part
explain
toler
observ
mice
pretreat
papmv
papmv
induc
upregul
pdc
despit
express
associ
product
heterogen
pdc
popul
describ
although
biolog
signific
phenomenon
still
larg
unknown
variou
report
howev
indic
two
subset
pdc
express
differ
set
marker
differenti
associ
product
follow
tlr
stimul
among
studi
suggest
express
could
discrimin
produc
pdc
pdc
weak
produc
pdc
strong
produc
thu
evalu
express
pdc
sought
determin
whether
could
explain
inhibit
product
observ
longer
period
papmv
treatment
previous
describ
pdc
spleen
mostli
figur
spleen
naiv
pdc
bone
marrow
although
still
major
figur
bone
marrow
naiv
display
larger
popul
spleen
immun
papmv
proport
pdc
express
increas
close
spleen
bone
marrow
figur
remain
elev
least
day
organ
distribut
express
among
pdc
return
naiv
control
level
day
postpapmv
immun
determin
express
profil
associ
product
perform
intracellular
stain
pdc
spleen
bone
marrow
mice
immun
papmv
h
prior
spleen
pdc
figur
howev
bone
marrow
pdc
express
papmv
immun
figur
signific
differ
denot
two
group
bone
marrow
niederquel
et
al
propos
pdc
could
precursor
pdc
regard
possibl
proport
pdc
fact
cell
upregul
respons
stimul
intracellular
stain
perform
h
postimmun
assess
progress
popul
respect
express
spleen
bone
marrow
differ
observ
three
time
point
data
shown
altogeth
result
indic
although
papmv
induc
express
product
seem
associ
express
experiment
set
antibodi
respons
longterm
attenu
respons
pdc
papmv
immun
result
suggest
inhibit
respons
multipl
administr
papmv
induc
share
mechan
tlrassoci
pathway
short
period
figur
papmvspecif
compon
affect
product
figur
well
pdc
activ
figur
longer
period
therefor
interest
assess
role
play
antibodi
refractori
state
induc
papmv
pretreat
know
shown
affect
respons
primeboost
vaccin
regimen
system
determin
antibodymedi
impact
papmv
pretreat
papmv
immun
use
jht
mice
lack
function
b
cell
consequ
also
lack
antibodi
observ
mice
figur
singl
immun
papmv
jht
mice
induc
product
figur
although
slightli
pronounc
fashion
papmv
pretreat
administ
day
prior
secondari
papmv
immun
product
follow
second
immun
equival
respons
naiv
anim
differ
significantli
result
obtain
mice
figur
sinc
product
affect
pretreat
examin
express
pdc
multitreat
papmv
similarli
observ
product
figur
express
pdc
significantli
differ
naiv
mice
papmv
pretreat
mice
receiv
papmv
immun
confirm
product
pdc
activ
jht
mice
due
absenc
antibodi
b
cell
perform
transfer
experi
immun
serum
sinc
two
differ
profil
observ
day
day
wildtyp
wt
mice
respect
inhibit
gener
papmv
pretreat
assess
kinet
igm
igg
product
serum
mice
papmv
immun
figur
expect
igm
igg
specif
papmv
found
serum
wt
mice
day
postimmun
day
postimmun
high
igg
titer
detect
transfer
carri
serum
collect
either
day
papmv
administr
pool
match
group
serum
equival
two
mice
inject
one
recipi
mous
immun
papmv
h
later
figur
product
assess
serum
h
postimmun
pdc
activ
assess
h
postimmun
inject
naiv
serum
affect
product
figur
compar
figur
affect
activ
pdc
shown
express
figur
compar
figur
howev
papmvimmun
serum
taken
day
administ
mice
follow
immun
papmv
show
product
figur
signific
decreas
express
pdc
figur
although
much
observ
wt
mice
altogeth
result
indic
papmvspecif
antibodi
play
signific
role
longterm
inhibit
attenu
immun
respons
follow
pretreat
papmv
long
treatment
choic
chronic
viral
infect
whether
use
alon
combin
treatment
ribavirin
treatment
hcv
due
toxic
medic
commun
move
away
treatment
toward
altern
bear
better
advers
event
profil
one
altern
toward
end
would
induc
endogen
product
host
instead
administ
high
dose
exogen
aim
use
papmv
nanoparticl
contain
noncod
ssrna
molecul
render
nonrepl
papmv
induc
product
pdc
without
caus
advers
effect
immun
toler
induc
viral
nanoparticl
frontier
immunolog
wwwfrontiersinorg
januari
volum
articl
administ
system
could
therefor
potenti
acceler
clearanc
persist
lcmv
infect
approach
would
also
potenti
applic
viral
infect
would
requir
express
virusspecif
antigen
observ
sequenti
applic
papmv
treatment
limit
attribut
regul
pathway
well
presenc
papmvspecif
antibodi
upon
first
immun
treatment
lcmv
infect
papmv
prove
ineffici
chang
viral
load
lcmvspecif
immun
respons
observ
follow
treatment
figur
like
papmv
lcmv
also
ligand
review
ref
therefor
possibl
stimul
lcmv
induc
tlr
toler
similar
observ
tlr
ligand
use
stimul
stimul
tlr
pathway
would
therefor
ineffici
lcmvinfect
mice
similarli
previou
research
shown
stimul
hbvinfect
hcvinfect
human
cell
tlr
ligand
unabl
induc
product
cytokin
activ
infect
dc
wherea
unabl
clear
lcmv
infect
use
papmv
administr
treatment
viral
infect
exogen
earli
cours
infect
shown
effici
control
lcmv
siv
rsv
note
success
treatment
lcmv
infect
wang
et
al
administ
subtyp
howev
subtyp
profil
elicit
papmv
yet
determin
thu
discrep
observ
could
due
differ
subtyp
given
dispar
immunomodulatori
effect
antivir
capac
born
differ
subtyp
furthermor
contrari
direct
inject
treatment
papmv
requir
uptak
nanoparticl
releas
degrad
ssrna
insid
endosom
produc
follow
activ
signal
cascad
although
sequenc
event
ensur
specif
safeti
like
suscept
variou
regulatori
mechan
lymphocyt
choriomening
viru
stimul
immun
cell
pathway
also
pathway
order
studi
mechan
play
set
isol
pathway
variabl
lcmv
infect
pretreat
mice
papmv
follow
second
immun
variou
time
point
approach
recapitul
result
observ
lcmvinfect
mice
almost
complet
abrog
product
pdc
activ
follow
secondari
papmv
immun
short
time
interv
immun
signific
impair
longer
interv
figur
similar
outcom
observ
product
variou
cytokin
chemokin
mcsf
rant
other
either
affect
enhanc
secondari
immun
figur
supplementari
materi
suggest
papmv
stimul
pathway
addit
lead
broad
activ
immun
system
pathway
might
differ
affect
multipl
papmv
administr
nonetheless
main
outcom
multipl
system
administr
papmv
least
pathway
suppress
secondari
respons
outcom
also
observ
previou
studi
indic
tlr
toler
discuss
posit
inabl
subsequ
papmv
immun
drive
robust
respons
may
also
depend
rout
administr
conclus
come
previou
find
show
sequenti
intranas
instil
could
potenti
papmv
treatment
previou
studi
immun
separ
seven
day
last
immun
led
higher
product
variou
cytokin
bronchoalveolar
lavag
intratumor
inject
model
also
observ
multipl
administr
papmv
led
decreas
tumor
growth
administ
alon
combin
immunotherapi
sustain
follow
multipl
administr
pretreat
papmv
therefor
abl
potenti
papmv
administr
deliv
local
limit
howev
observ
papmv
administ
system
shown
studi
develop
immun
regimen
altern
variou
administr
rout
could
therefor
interest
altern
mitig
pitfal
sequenti
system
treatment
regard
toler
tlr
found
degrad
play
central
role
agreement
studi
illustr
kinas
share
across
tlr
pathway
degrad
follow
stimul
although
degrad
shown
last
least
h
poststimul
vivo
vitro
length
refractori
period
yet
determin
show
stimul
bmpdc
papmv
induc
partial
degrad
observ
flow
cytometri
later
confirm
immunoblot
figur
note
observ
stronger
degrad
papmv
might
due
differ
natur
agonist
inde
small
synthet
molecul
requir
uptak
reach
endosom
cell
therefor
easier
faster
molecul
reach
cell
induc
degrad
robust
fashion
hand
papmv
particul
molecul
taken
immun
cell
reach
endosom
thu
elong
interv
stimul
appar
degrad
would
also
particular
interest
verifi
regul
pdc
vivo
howev
due
low
proport
pdc
spleen
limit
conduct
analys
vitro
determin
regul
bmpdc
import
note
result
reveal
partial
role
play
toler
observ
follow
multipl
administr
papmv
inde
stimul
bmpdc
papmv
induc
complet
degrad
suggest
could
residu
protein
left
cell
capabl
proceed
signal
cascad
encount
papmv
led
us
investig
potenti
inhibitori
mechan
niederquel
et
al
suggest
express
could
discrimin
subset
pdc
abl
produc
respons
tlr
stimul
therefor
hypothes
sequenti
papmv
administr
could
preferenti
stimul
expand
pdc
subset
unabl
produc
might
explain
abrog
product
upon
secondari
immun
howev
system
express
pdc
associ
capac
produc
respons
papmv
use
particul
molecul
niederquel
et
al
use
cpg
odn
ligand
given
stimul
ligand
rna
vs
dna
similar
cpg
odn
small
synthet
molecul
kinet
activ
therefor
differ
model
regard
marker
also
associ
product
might
inform
administr
plant
viruslik
particl
mice
lead
rapid
product
specif
antibodi
review
ref
sinc
antibodi
gener
follow
papmv
inject
interest
assess
impact
multipl
administr
regimen
show
immun
jht
mice
devoid
b
cell
antibodi
well
perform
serum
transfer
papmvspecif
antibodi
gener
first
administr
larg
respons
toler
second
papmv
inject
shortterm
immun
regimen
day
retain
inhibit
pdc
activ
jht
mice
shown
slightli
diminish
express
follow
second
immun
rel
naiv
group
figur
transfer
papmv
immun
serum
day
postimmun
naiv
mice
follow
papmv
immun
observ
lower
express
level
compar
mice
receiv
singl
papmv
administr
figur
compar
figur
either
due
underli
mechan
independ
antibodi
due
titer
antibodi
transfer
although
titer
papmv
specif
antibodi
found
mice
receiv
serum
transfer
lower
found
papmv
immun
mice
figur
supplementari
materi
enough
interfer
subsequ
papmv
immun
inhibit
product
day
overcom
limit
one
could
administ
immunogen
distinct
plant
viruslik
particl
circumv
effect
antibodi
would
also
interest
explor
use
differ
inject
rout
whether
antibodi
also
interfer
respons
subsequ
inject
direct
current
assess
potenti
system
administ
papmv
previous
shown
platform
could
modifi
order
display
variou
epitop
surfac
nanoparticl
engin
particl
show
immunostimulatori
properti
similar
sometim
better
origin
platform
follow
immun
new
strategi
current
investig
use
sortasemedi
antigen
coupl
techniqu
permit
fusion
epitop
directli
surfac
papmv
without
need
genet
modifi
sequenc
coat
protein
immun
papmvfus
platform
lead
develop
protect
humor
respons
differ
immun
regimen
well
differ
chronic
viral
infect
model
could
test
evalu
potenti
papmv
treat
diseas
result
obtain
studi
open
way
studi
potenti
use
papmv
treatment
autoimmun
diseas
previous
shown
absenc
whether
ifnardefici
mice
use
ifnar
antibodi
blockad
autoimmun
symptom
lupu
prone
mice
improv
multipl
system
administr
papmv
induc
inhibit
product
provid
potenti
therapeut
approach
applic
studi
show
treatment
chronic
viru
infect
papmv
limit
still
need
improv
although
singl
administr
papmv
induc
strong
immun
respons
recal
system
immun
much
less
potent
partli
due
degrad
mainli
interfer
papmvspecif
antibodi
result
also
demonstr
papmv
platform
abl
induc
immun
respons
follow
pretreat
although
yet
degre
would
abl
clear
ongo
viral
infect
although
outcom
favor
context
chronic
viral
infect
could
interest
diseas
autoimmun
improv
therefor
need
promis
therapeut
approach
use
treatment
chronic
viral
infect
ifndepend
chronic
diseas
studi
carri
accord
recommend
canadian
council
anim
care
guidelin
protocol
approv
institut
nation
de
la
recherch
scientifiqu
anim
care
committe
figur
multiplex
quantif
cytokin
chemokin
serum
h
follow
last
immun
papmv
immun
perform
day
follow
first
immun
papmv
n
five
mice
per
group
figur
express
kinet
plasmacytoid
dendrit
cell
papmv
immun
result
present
ratio
mfi
sampl
averag
mean
fluoresc
intens
control
n
one
three
mice
per
group
figur
elisa
quantif
papmvspecif
igg
serum
mice
transfer
immun
sera
h
follow
immun
control
papmv
immun
sera
collect
day
follow
papmv
immun
n
two
three
mice
per
group
refer
